All In Biotech

Drug Trial Radar · NCT07645235

A Study to Evaluate Gepotidacin Exposure in Breast Milk of Healthy Lactating Women

A Phase 1 Open-Label, Single Dose Study to Evaluate the Pharmacokinetics of Gepotidacin in Healthy Lactating Women

Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

8

Planned (sponsor's estimate)

Start

Jul 23, 2026

Primary completion

May 17, 2027

Study completion May 17, 2027

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
Collaborators
Biomedical Advanced Research and Development Authority
First posted
Jun 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study aims to evaluate the pharmacokinetic of gepotidacin in fed healthy lactating women.

Conditions

  • Urinary Tract Infections

Interventions

  • GepotidacinDrug

    A single oral dose of 3000 mg gepotidacin will be administered

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the concentration-time curve from time zero to the last measurable concentration time point (t) (AUC[0 to t]) of gepotidacin in breast milkTime frame: Up to 48 hours post dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Las Vegas, Nevada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.